Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37results about How to "Prevention and improvement" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dual-purpose pliers adapted to chain link
InactiveUS20110154958A1Avoid it happening againPrevention and improvementPliersMetal-working hand toolsEngineeringDual purpose
A dual-purpose pliers adapted to chain link applies to concurrently promote a separation of two first jaw parts or an approach of two second jaw parts, which is conducive to a convenient detachment or assemblage of a master chain link via merely using a driving tool. Further, each jaw part forms a curved brim represented by an arcuate contour, a serrated shape, or the combination thereof. Accordingly, the curved brim serves to encircle and lean against a periphery of a chain pin of the chain for a stable manipulation.
Owner:WANG WEN PIN
Agent having neurotrophic factor-like activity
InactiveUS20100204498A1Improve securityPrevention and improvementNervous disorderOrganic chemistryFactor iiEthyl ester
The present invention provides a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which contains, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms (C10) to 12 carbon atoms (C12) or fatty acid esters thereof, such as 3,7-dimethyloctanoic acid ethyl ester, geranic acid ethyl ester, and the like, each of which has 8 carbon atoms (C8), decanoic acid methyl ester, trans-2-decenoic acid, trans-2-decenoic acid methyl ester, trans-2-decenoic acid ethyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-9-decenoic acid methyl ester, and the like, each of which has 10 carbon atoms (C10), trans-10-undecenoic acid methyl ester, trans-10-undecenoic acid ethyl ester, and the like, each of which has 11 carbon atoms (C11), and dodecanoic acid, and the like, each of which has 12 carbon atoms (C12), or salts thereof or prodrugs thereof.
Owner:NAGOYA INDUSTRIAL SCIENCE RESEARCH INST
Agent for improving nervous system cell functions
InactiveUS20090246186A1Improve and prevent central neurological diseaseImprove cell functionSenses disorderNervous disorderDiseaseNervous system
The present invention aims to activate neural cells in brain, and further provide a useful composition having an action to protect intracerebral neural cells from external and internal stresses.An agent for improving a neural cell function containing reduced coenzyme Q as an active ingredient, more specifically, an agent for activating neural cells and an agent for protecting neural cells, is useful, and can be used for the improvement or prophylaxis of central neurological diseases or neuropathy symptoms derived from or associated with a neurodegenerative disease, promotion of cognitive function or improvement of learning and memory disorders.
Owner:KANEKA CORP
High protein supplement
ActiveUS7982066B2Prevention and improvementImbalance conditionOrganic active ingredientsNervous disorderProtein C deficiencyProtein
The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine, and / or L-Histidine.
Owner:SCHEELE GEORGE
Tgf-Beta Binding Antibodies
InactiveUS20080292638A1Prevention and improvementAntibody mimetics/scaffoldsAntipyreticHigh affinity antibodyAntigen binding
Owner:ELI LILLY & CO
Combination of effective substances causing synergistic effects of multiple targeting and use thereof
InactiveUS9526718B2Good curative effectPrevention and improvementCosmetic preparationsNervous disorderGlycineAtopic dermatitis
Disclosed are a combination of active components inducing synergistic effects of multi-targeting and a use thereof. More particularly, disclosed are a functional food composition, a cosmetic composition, a pain-suppressive composition, and a composition for treatment or prevention of pruritus or atopic dermatitis, which comprise as active components, two or more components selected from a group consisting of (a) a 5-hydroxytryptamine subtype 2 (5-HT2) receptor antagonist; (b) a P2X receptor antagonist; and (c) any one of a glycine receptor agonist, a glycine transporter (GlyT) antagonist, a gamma-aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GAT1) antagonist.
Owner:VIVOZON
Anti-allergy composition comprising wood vinegar- or bamboo vinegar-distilled solution
The anti-allergy composition of the present invention comprises, as an ineffective ingredient, a wood vinegar-distilled solution. A bamboo vinegar-distilled solution obtained using a bamboo as a wood material is preferable. Also, it is preferable that the present composition does not contain benzopyrene, dibenzanthracene, and methylcholanthrene substantially. The anti-allergy composition can exhibit an anti-allergy effect by oral ingestion. In particular, it is useful for inhibiting Type I allergy such as allergic rhinitis, hay fever, allergic conjunctivitis, atopic dermatitis, allergic asthma, urticaria, food allergy, and anaphylaxis. In addition, the composition can be also applied to a skin. When a wood is subjected to smoking treatment at 130 to 170° C., dried, and then carbonized at 350 to 450° C., a smoke discharged during this carbonization treatment is condensed to obtain a crude wood vinegar, and then the crude wood vinegar is distilled at a low temperature of 50 to 60° C. under reduced pressure to obtain a wood vinegar-distilled solution.
Owner:YAMANASHI YAKUKEN +1
An agent for improving mitochondrial function
InactiveUS20170312200A1Improve mitochondrial functionPrevent skin agingCosmetic preparationsPreparation by ester-hydroxy reactionArylHelvolic acid
Provided is an agent for improving mitochondrial function including a hydroxycitric acid derivative represented by the following Formula (I) or a salt thereof, as an active ingredient [(In Formula (I), R1 and R2 each independently represent a hydrogen atom or any one group selected from the group represented by the following Formula (Ia) (here, R1 and R2 do not represent hydrogen atoms at the same time), X1 to X3 each independently represent a nitrogen or an oxygen atom, and R3, R4, R5, R3′ R4′, and R5′ each independently represent a hydrogen atom, or a chained hydrocarbon group (here, in a case where X1, X2, and X3 each independently represent an oxygen atom, corresponding R3′, R4′, or R5′ does not exist). In Formula (Ia), R6 to R8 each independently represent a hydrogen atom, an aryl group, or a chained hydrocarbon group having 1 to 30 carbon atoms].
Owner:SHOWA DENKO KK
Agent having neurotrophic factor-like activity
InactiveUS20120264959A1Improve securityPreventive andBiocideNervous disorderEthyl esterCiliary neurotrophic factor
Owner:NIPPON ZOKI PHARM CO LTD
Hemodynamics improving agent
InactiveUS20080171781A1Lower blood pressureIncreased vascular resistanceBiocideOrganic chemistryEndocrinologyActive ingredient
Agents which contains a serotonin derivative as an active ingredient are effective for improving hemodynamics and for preventing or improving deterioration of hemodynamics associated with aging and progression of cardiovascular diseases.
Owner:AJINOMOTO CO INC
Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
ActiveUS20130225837A1Excellent neurotrophic factor-like activityHighly safe preventiveNervous disorderFatty acid chemical modificationDecenoic AcidAnticarcinogen
An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1):(In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.
Owner:NAGOYA INDUSTRIAL SCIENCE RESEARCH INST +1
Mixture having effect of improving insulin resistance, effect of suppressing body weight gain, and effect of preventing and improving fatty liver
InactiveUS20080268069A1Improve insulin resistanceSuppressing body weight gainBiocideOrganic active ingredientsFatty liverBody weight
The specification discloses a mixture obtained by mixing trivalent chromium and an onion extract, which has the effect of improving insulin resistance, suppressing body weight and preventing and improving fatty liver. Preferably the trivalent chromium is in a form of trivalent chromium-nicotinic acid complex.
Owner:RYUSENDO
Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof
InactiveUS20090318552A1Promote insulin secretionPreventing and treating diabetes mellitusBiocideOrganic chemistryFood additiveAdditive ingredient
The present invention relates to a composition for preventing and treating diabetes mellitus that includes a shikonin compound as an active ingredient and to a use thereof. More particularly, the present invention relates to a composition for preventing and treating diabetes mellitus that includes isobutyryl shikonin, β,β-dimethylacryl shikonin, isovaleryl shikonin, or α-methyl-n-butyryl shikonin as an active ingredient and to a use thereof. The composition of the present invention exhibits antidiabetic effects by blocking the KATP ion channels (ATP-sensitive potassium ion channels) of beta (β) cells in the pancreas and increasing the concentration of calcium ions to promote the secretion of insulin, and thus can be used as a medicinal pharmaceutical, food additive, or health functional food for preventing and treating diabetes mellitus.
Owner:JIN DO COUNTY
Sirt 1 activator including syringaresinol
ActiveUS20140371307A1High expressionHigh activityBiocideSenses disorderMedicineBULK ACTIVE INGREDIENT
The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
Owner:AMOREPACIFIC CORP
Bearing and bearing arrangement
A spherical roller bearing is provided having an outer ring that includes at least one inner raceway, an inner ring that includes a first and a second outer raceway, a plurality of roller elements disposed in a first and second roller row between the at least one inner raceway and the first and second outer raceway, a cage for one of guiding and retaining the roller elements in the first and second roller row, the cage includes a plurality of cage pockets, in which one of the plurality pf rollers is disposed within each cage pocket. The bearing further provides a specific pitch circle diameter (PCD), and when the cage is under-pitch roller centered in relation to the pitch circle diameter (PCD). In addition, a bearing arrangement and a wind turbine bearing arrangement is disclosed.
Owner:AB SKF
Composition for preventing, ameliorating, or treating neurological disease containing osmotin peptide as active ingredient
ActiveUS20180036365A1Improve survivabilityNo significant cytotoxicityNervous disorderPeptide/protein ingredientsDiseaseBULK ACTIVE INGREDIENT
A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.
Owner:IND ACADEMIC COOP FOUND GYEONGSANG NAT UNIV
Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
ActiveUS8987486B2Excellent neurotrophic factor-like activityHighly safe preventive and therapeutic agentBiocideNervous disorderDecenoic AcidSide effect
Owner:NAGOYA INDUSTRIAL SCIENCE RESEARCH INST +1
Anti-allergy composition comprising wood vinegar- or bamboo vinegar-distilled solution
InactiveUS7214393B2Improve securityAvoid reactionBiocideSenses disorderAdditive ingredientCarbonization
The anti-allergy composition of the present invention comprises, as an ineffective ingredient, a wood vinegar-distilled solution. A bamboo vinegar-distilled solution obtained using a bamboo as a wood material is preferable. Also, it is preferable that the present composition does not contain benzopyrene, dibenzanthracene, and methylcholanthrene substantially. The anti-allergy composition can exhibit an anti-allergy effect by oral ingestion. In particular, it is useful for inhibiting Type I allergy such as allergic rhinitis, hay fever, allergic conjunctivitis, atopic dermatitis, allergic asthma, urticaria, food allergy, and anaphylaxis. In addition, the composition can be also applied to a skin. When a wood is subjected to smoking treatment at 130 to 170° C., dried, and then carbonized at 350 to 450° C., a smoke discharged during this carbonization treatment is condensed to obtain a crude wood vinegar, and then the crude wood vinegar is distilled at a low temperature of 50 to 60° C. under reduced pressure to obtain a wood vinegar-distilled solution.
Owner:YAMANASHI YAKUKEN +1
Bearing and bearing arrangement
A spherical roller bearing is provided having an outer ring that includes at least one inner raceway, an inner ring that includes a first and a second outer raceway, a plurality of roller elements disposed in a first and second roller row between the at least one inner raceway and the first and second outer raceway, a cage for one of guiding and retaining the roller elements in the first and second roller row, the cage includes a plurality of cage pockets, in which one of the plurality pf rollers is disposed within each cage pocket. The bearing further provides a specific pitch circle diameter (PCD), and when the cage is under-pitch roller centered in relation to the pitch circle diameter (PCD). In addition, a bearing arrangement and a wind turbine bearing arrangement is disclosed.
Owner:AB SKF
Bearing and bearing arrangement
ActiveUS9732793B2Adaptable and usefulMitigate such drawbackRoller bearingsShaftsAxial forceEngineering
A spherical roller bearing having an outer ring providing at least one inner raceway, an inner ring providing a first and a second outer raceway, a plurality of roller elements arranged in a first and second roller row in-between the at least one inner raceway and the respective first and second outer raceway is provided. The bearing provides a cage for guiding the roller elements in the first and second roller row, the cage includes a plurality of cage pockets, wherein in each cage pocket one of the roller elements is disposed. The bearing further presents a specific pitch circle diameter (PCD), and the cage is essentially in-pitch roller centered in relation to the pitch circle diameter (PCD) when there is an axial force acting on the bearing. In addition, the present invention regards a bearing arrangement and a wind turbine bearing arrangement.
Owner:AB SKF
Sirt 1 activator including syringaresinol
Owner:AMOREPACIFIC CORP
Novel gene relating to fibrotic conditions
InactiveUS20060142222A1Improving and preventing organ fibrosisExpression quantityCompound screeningFungiCell-Extracellular MatrixFibrosis
This discloses a novel human or rat polypeptide useful in improving and / or preventing organ fibrosis and a polynucleotide encoding the aforementioned polypeptide, an expression vector containing the aforementioned polynucleotide, and a cell transfected with the aforementioned expression vector. The aforementioned polynucleotide shows a remarkable decrease in the expression dose in the kidney of a chronic renal insufficiency model rat and in the bladder of a rat suffering from the induction of fibrotic conditions in the bladder, compared with a normal individual. Also, the production of extracellular matrix is suppressed by overexpression of the aforementioned polypeptide. Also disclosed are the promoter region of the aforementioned polypeptide, a method for screening a remedy for fibrotic conditions, and a process for producing a medicinal composition for improving fibrotic conditions which contains a substance obtained by the aforementioned screening method as the active ingredient.
Owner:ASTELLAS PHARMA INC
Composition for the prevention, improvement, or treatment of neurological disorder including adiponectin receptor-activating novel peptide as active ingredient
ActiveUS20180312540A1Improve productivityFunction increaseNervous disorderPeptide/protein ingredientsAmyloid betaCytotoxicity
A method for preventing, improving or treating a neurological disorder includes administering to a subject a composition including an adiponectin receptor-activating novel peptide as an active ingredient. The adiponectin receptor-activating novel peptide is a peptide consisting of 5 amino acids, and when the adiponectin receptor-activating novel peptide is administered to Alzheimer's model mice, the mice's behavioral changes show that memory and cognitive functions are significantly increased, and APP and amyloid beta (Aβ) proteins are significantly reduced, cytotoxicity does not occur, the proliferation rate of neurons is increased, and cell death is inhibited.
Owner:IND ACADEMIC COOP FOUND GYEONGSANG NAT UNIV
Peptide having hair growth promoting activity and use thereof
PendingUS20220265538A1Inhibit expressionPromoting hair generation hairCosmetic preparationsHair cosmeticsPharmaceutical drugHair growth
Provided are a peptide having an activity of promoting hair generation and use thereof. In particular, provided are a peptide consisting of an amino acid sequence of SEQ ID NO: 1, a composition including the peptide for improving hair loss or promoting hair generation, and a pharmaceutical composition including the peptide for preventing or treating hair loss.
Owner:CAREGEN
Sirt 1 activator including syringaresinol
ActiveUS20160263079A1High expressionHigh activitySenses disorderAntipyreticMedicineBULK ACTIVE INGREDIENT
Owner:AMOREPACIFIC CORP
1,2-diacylglycerol compound, preparation method therefor, and immunomodulator containing same as active ingredient
PendingUS20210002197A1Prevention and improvementPreparation from carboxylic acid halidesOrganic compound preparationCytokineDiacyl glycerol
Disclosed are a novel 1,2-diacylglycerol compound that useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4 and IL-6 or chemokine CXCL8 related to the migration of inflammatory cells, a method for preparing the same, and an immunomodulator containing the same as an active ingredient. The 1,2-diacylglycerol compound is represented by Chemical Formula 2 in the patent specification.
Owner:ENZYCHEM LIFESCI CORP
Sirt 1 activator including syringaresinol
ActiveUS20160263077A1High expressionHigh activitySenses disorderAntipyreticMedicineBULK ACTIVE INGREDIENT
Owner:AMOREPACIFIC CORP
Bearing
ActiveUS9797440B2Easy to useMitigate such drawbackRoller bearingsShaftsEngineeringMechanical engineering
The present disclosure regards a spherical roller bearing having, an outer ring providing at least one inner raceway, an inner ring providing a first and a second outer raceway, a plurality of roller elements arranged in a first and second roller row disposed between the at least one inner raceway and the respective first and second outer raceway, the roller elements further providing axially inner ends. Moreover, the bearing includes a cage for one of guiding and retaining the roller elements in the first and second roller row, the cage including a plurality of cage pockets, wherein one of the roller elements is disposed within each cage pocket, and wherein the cage is roller centered by the axially inner ends.
Owner:AB SKF
Composition for preventing, ameliorating, or treating neurological disease containing osmotin peptide as active ingredient
ActiveUS10471119B2Improve survivabilityNo significant cytotoxicityNervous disorderPeptide/protein ingredientsDiseaseCytotoxicity
A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.
Owner:IND ACADEMIC COOP FOUND GYEONGSANG NAT UNIV
Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
ActiveUS20200247795A1Prevent and improve and treat various diseaseInhibition effectCosmetic preparationsOrganic chemistryNicotinamide phosphoribosyltransferaseMedicinal chemistry
The present invention relates to a novel compounds for inhibiting nicotinamide phosphoribosyltransferase (NamPT), a composition comprising the same, and various uses thereof.
Owner:CHECKMATE THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com